Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanzi Huangshi Pill is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine for the treatment of myelodysplastic syndromes (MDS). The formula is composed of three 'seed' herbs—*Psoralea corylifolia* (Buguzhi), *Cuscuta chinensis* (Tusizi), and *Lycium barbarum* (Gouqizi)—along with *Realgar* (Xionghuang), a mineral containing arsenic sulfide. The mechanism of action involves the induction of apoptosis and cell differentiation in dysplastic myeloid cells, primarily driven by the arsenic components, while the herbal constituents are intended to tonify the kidney and support bone marrow hematopoiesis. It is specifically studied in patients with low-risk MDS to improve anemia and other cytopenias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanzi Huangshi Pill.